ATXN2 and amyotrophic lateral sclerosis: Targeting ATXN2 for ALS treatment. Due to the link between ataxin-2 levels and TDP-43 related toxicity, strategies to reduce ataxin-2 levels were developed to mitigate TDP-43 pathology in ALS.